Axikin Pharmaceuticals signed on Proteros Fragments to discover customized lead compounds for the treatment of inflammatory diseases. Proteros aims to generate multiple advanced lead molecules that inhibit a target protein supplied by Axikin.
In the initial stages of the program Proteros will solve the x-ray structure of this protein, develop assays, and identify active fragments from its library. It will also determine the binding mode of the fragments to the target protein using its crystallography platform. In the second phase, Proteros’ chemists will evolve the selected fragments into a lead series meeting specific criteria including demonstrated activity and selectivity.
Proteros will receive research funding and success milestone payments including fees if compounds arising out of the collaboration advance to clinical development.